Papillitis associated with IgLON5 autoimmunity: A novel clinical phenotype.

Autor: Li X; Department of Neurology, Mayo Clinic, Rochester, USA., Chen JJ; Department of Neurology, Mayo Clinic, Rochester, USA; Department of Ophthalmology, Mayo Clinic, Rochester, USA; Center of MS and Autoimmune Neurology, Mayo Clinic, Rochester, USA., Hur M; Department of Neurology, Mayo Clinic, Rochester, USA; Department of Ophthalmology, Mayo Clinic, Rochester, USA., Paton GR; Casey Eye Institute Division of Neuro-ophthalmology, Oregon Health & Science University, USA., McKeon A; Department of Neurology, Mayo Clinic, Rochester, USA; Center of MS and Autoimmune Neurology, Mayo Clinic, Rochester, USA; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, USA., Zekeridou A; Department of Neurology, Mayo Clinic, Rochester, USA; Center of MS and Autoimmune Neurology, Mayo Clinic, Rochester, USA; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, USA. Electronic address: zekeridou.anastasia@mayo.edu.
Jazyk: angličtina
Zdroj: Journal of neuroimmunology [J Neuroimmunol] 2024 Mar 15; Vol. 388, pp. 578312. Date of Electronic Publication: 2024 Feb 05.
DOI: 10.1016/j.jneuroim.2024.578312
Abstrakt: Objectives: To describe papillitis as a clinical phenotype of IgLON5 autoimmunity.
Methods: We retrospectively reviewed patients with IgLON5 autoimmunity who had optic neuropathy, optic neuritis, or optic disc edema. Sera from patients with recurrent papillitis were tested for IgLON5 antibodies.
Results: We found two elderly males presenting with papillitis in the presence of IgLON5 antibodies. CSF pleocytosis was present and partial vision improvement occurred in one patient despite immunotherapy. Sera from 18 patients with recurrent papillitis were negative for IgLON5 antibodies.
Conclusion: Papillitis could be a manifestation of IgLON5 disease, with or without accompanying cognitive, sleep, and movement disorders.
Competing Interests: Declaration of competing interest John J. Chen serves as a consultant for UCB and Horizon; Andrew McKeon reports research funding from the National Institutes of Health (NIH: RO1NS126227, U01NS120901), patents issued for GFAP and MAP1B-IgGs and patents pending for PDE10A, Septins-5 and -7, and KLCHL11-IgGs, and has consulted for Janssen and Roche pharmaceuticals, without personal compensation; Anastasia Zekeridou reports patents pending for PDE10A-IgG, Tenascin-R-IgG and DACH1-IgG as biomarkers of neurological autoimmunity; research funding from Roche not relevant to the current project; consulting for Alexion Pharmaceuticals with no personal compensation.
(Copyright © 2023. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: